The Times Australia
Google AI
The Times World News

.

A major ivermectin study has been withdrawn, so what now for the controversial drug?

  • Written by Andrew McLachlan, Head of School and Dean of Pharmacy, University of Sydney
A major ivermectin study has been withdrawn, so what now for the controversial drug?

Ivermectin[1], an existing drug against parasites including head lice, has had a chequered history when it comes to treating COVID-19.

The bulk of studies so far show there’s not enough evidence[2] ivermectin is useful in treating or preventing COVID-19, either alone or with antibiotics or supplements.

Yet interest in the drug remains, on social media, in some countries, with some doctors[3] and with one politician in particular, Liberal MP Craig Kelly, touting its benefits[4].

Now a large clinical trial that seemed to show positive results for ivermectin has been withdrawn[5]. So you’d think that would be end of the ivermectin saga.

But research into ivermectin is ongoing. Here’s what the evidence says so far and what we can expect next.

Read more: How to deal with the Craig Kelly in your life: a guide to tackling coronavirus contrarians[6]

How was ivermectin even a contender?

Ivermectin was identified as a potential COVID-19 treatment based on experiments in isolated cells[7] and animals[8]. The initial lab studies into ivermectin’s effect on the coronavirus involved very high concentrations[9] of the drug. These were many times higher than can be achieved in the body at doses recommended to treat parasites.

As the pandemic progressed, so did ivermectin clinical trials. But when experts who write doctors’ prescribing guidelines reviewed the data, they found not enough evidence to back ivermectin to treat or prevent COVID-19. These groups included Australia’s National COVID-19 Clinical Evidence Taskforce[10] and the World Health Organization[11]. Instead, they said ivermectin should only be used in clinical trials[12].

Read more: Ivermectin is still not a miracle cure for COVID-19, despite what you may have read[13]

The most robust summary of the evidence[14] for ivermectin in COVID-19, published in June, goes one step further. It found available evidence showed ivermectin didn’t work.

This review carefully examined ten higher-quality (randomised-controlled) clinical trials, which involved more than 1,100 patients with COVID-19 being treated with ivermectin.

The researchers excluded many of the low-quality (observational) studies some commentators have used to support ivermectin as a COVID-19 treatment. This was because observational studies cannot control other clinical factors that might influence how people respond to COVID-19, such as other treatments and supportive care.

This major review concluded ivermectin did not reduce death from any cause, the length of stay in hospital or people’s ability to clear the virus. The review also said ivermectin was safe but “not a viable option” to treat COVID-19.

Read more: Head lice drug Ivermectin is being tested as a possible coronavirus treatment, but that's no reason to buy it[15]

But what about the withdrawn study?

In recent months, we heard the seemingly promising results from a large randomised trial[16], which was posted online as a pre-print[17] and had not been independently verified (peer reviewed).

This study stood out because it found ivermectin led to “a substantial improvement and reduction in mortality rate in ivermectin treated groups” — by 90%.

However, the excitement was tempered when the pre-print was withdrawn[18] pending a “formal investigation”. Significant questions were asked[19] about the nature of the primary data on which the study was based and whether some of the paper had been plagiarised, among other issues. This called into question[20] the spectacular positive result for ivermectin.

The trial and publication are still under investigation.

Read more: Stopping, blocking and dampening – how Aussie drugs in the pipeline could treat COVID-19[21]

Surely, that’s the end of ivermectin now?

But the ivermectin story continues. Researchers at the University of Oxford announced in June they would be starting another ivermectin trial[22], called PRINCIPLE[23].

This high-quality trial will involve investigating treatments for people at more risk of serious COVID-19. So far the trial has recruited more than 5,000 volunteers from across the UK. Another part of the trial (into another potential COVID-19 therapy) has already reported results[24].

This new ivermectin trial is just starting and will compare a three-day treatment of ivermectin in people within the first 14 days of COVID-19 symptoms, or having a positive test, with those having usual care. The trial is expected to report its results in the coming months.

What next?

Ivermectin remains a medicine of interest for treating and preventing COVID-19. Yet, key questions remain including the best ivermectin dose, how long ivermectin should be taken and when it should be given to people with COVID based on their stage of infection and illness.

Until then, getting vaccinated[25] will give you the best chance of avoiding severe COVID rather than waiting for a COVID treatment, which may or may not be shown to work.

Read more: How well do COVID vaccines work in the real world?[26]

References

  1. ^ Ivermectin (theconversation.com)
  2. ^ not enough evidence (theconversation.com)
  3. ^ some doctors (www1.racgp.org.au)
  4. ^ touting its benefits (www.sbs.com.au)
  5. ^ withdrawn (www.theguardian.com)
  6. ^ How to deal with the Craig Kelly in your life: a guide to tackling coronavirus contrarians (theconversation.com)
  7. ^ isolated cells (www.sciencedirect.com)
  8. ^ animals (www.biorxiv.org)
  9. ^ very high concentrations (www.ncbi.nlm.nih.gov)
  10. ^ National COVID-19 Clinical Evidence Taskforce (covid19evidence.net.au)
  11. ^ World Health Organization (www.who.int)
  12. ^ clinical trials (app.magicapp.org)
  13. ^ Ivermectin is still not a miracle cure for COVID-19, despite what you may have read (theconversation.com)
  14. ^ most robust summary of the evidence (academic.oup.com)
  15. ^ Head lice drug Ivermectin is being tested as a possible coronavirus treatment, but that's no reason to buy it (theconversation.com)
  16. ^ large randomised trial (www.researchsquare.com)
  17. ^ pre-print (www.thelancet.com)
  18. ^ pre-print was withdrawn (www.theguardian.com)
  19. ^ Significant questions were asked (steamtraen.blogspot.com)
  20. ^ called into question (grftr.news)
  21. ^ Stopping, blocking and dampening – how Aussie drugs in the pipeline could treat COVID-19 (theconversation.com)
  22. ^ another ivermectin trial (www.principletrial.org)
  23. ^ PRINCIPLE (www.principletrial.org)
  24. ^ results (www.principletrial.org)
  25. ^ getting vaccinated (www.mja.com.au)
  26. ^ How well do COVID vaccines work in the real world? (theconversation.com)

Read more https://theconversation.com/a-major-ivermectin-study-has-been-withdrawn-so-what-now-for-the-controversial-drug-164627

Times Magazine

Australia’s supercomputers are falling behind – and it’s hurting our ability to adapt to climate change

As Earth continues to warm, Australia faces some important decisions. For example, where shou...

Australia’s electric vehicle surge — EVs and hybrids hit record levels

Australians are increasingly embracing electric and hybrid cars, with 2025 shaping up as the str...

Tim Ayres on the AI rollout’s looming ‘bumps and glitches’

The federal government released its National AI Strategy[1] this week, confirming it has dropped...

Seven in Ten Australian Workers Say Employers Are Failing to Prepare Them for AI Future

As artificial intelligence (AI) accelerates across industries, a growing number of Australian work...

Mapping for Trucks: More Than Directions, It’s Optimisation

Daniel Antonello, General Manager Oceania, HERE Technologies At the end of June this year, Hampden ...

Can bigger-is-better ‘scaling laws’ keep AI improving forever? History says we can’t be too sure

OpenAI chief executive Sam Altman – perhaps the most prominent face of the artificial intellig...

The Times Features

In awkward timing, government ends energy rebate as it defends Wells’ spendathon

There are two glaring lessons for politicians from the Anika Wells’ entitlements affair. First...

Australia’s Coffee Culture Faces an Afternoon Rethink as New Research Reveals a Surprising Blind Spot

Australia’s celebrated coffee culture may be world‑class in the morning, but new research* sugge...

Reflections invests almost $1 million in Tumut River park to boost regional tourism

Reflections Holidays, the largest adventure holiday park group in New South Wales, has launched ...

Groundbreaking Trial: Fish Oil Slashes Heart Complications in Dialysis Patients

A significant development for patients undergoing dialysis for kidney failure—a group with an except...

Worried after sunscreen recalls? Here’s how to choose a safe one

Most of us know sunscreen is a key way[1] to protect areas of our skin not easily covered by c...

Buying a property soon? What predictions are out there for mortgage interest rates?

As Australians eye the property market, one of the biggest questions is where mortgage interest ...

Last-Minute Christmas Holiday Ideas for Sydney Families

Perfect escapes you can still book — without blowing the budget or travelling too far Christmas...

98 Lygon St Melbourne’s New Mediterranean Hideaway

Brunswick East has just picked up a serious summer upgrade. Neighbourhood favourite 98 Lygon St B...

How Australians can stay healthier for longer

Australians face a decade of poor health unless they close the gap between living longer and sta...